icaritin profile

icaritin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	5318980
CHEMBL ID	498485
SCHEMBL ID	4223542
MeSH ID	M0483270

Synonym
BIDD:ER0021
118525-40-9
4h-1-benzopyran-4-one, 3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)-
3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4h-1-benzopyran-4-one
bdbm50272527
3-hydroxy-7-o-beta-glucose-8-prenyl-4''-methoxy chrysin
sgn162
CHEMBL498485 ,
sgn-162
icaritin
3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)chromen-4-one
unii-ufe666uely
ufe666uely ,
S9080
FT-0670266
NCGC00345813-01
4h-1-benzopyran-4-one, 3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-
AKOS015896858
icaritin [who-dd]
TUUXBSASAQJECY-UHFFFAOYSA-N
MLS006010055
smr004701218
CS-3679
SCHEMBL4223542
AC-33950
HY-N0678
I0974
DTXSID00152154
icartin
icaritin, >=98% (hplc)
icaritin(anhydroicaritin)
DB12672
3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-4h-chromen-4-one
mfcd22422519
cycloicaritin
BCP32968
NCGC00345813-04
CCG-268265
Q27291061
AS-55987
4'-methoxy-3,5,7trihydroxy-8-3,3-dimethylallylflavone
3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-4h-chromen-4-one

Excerpt	Reference	Relevance
"Icaritin is an active ingredient in "	( Design, Synthesis, and Biological Evaluation of Icaritin Derivatives as Novel Putative DEPTOR Inhibitors for Multiple Myeloma Treatment. Cheng, H; Hou, Y; Kuang, W; Liu, Z; Min, W; Pu, S; Sun, C; Wang, L; Wang, X; Xiao, Y; Xin, GZ; Yang, P; Yuan, K; Zhang, F, 2021)	2.32
"Icaritin (ICT) is a metabolite of icariin (ICA), which are two active flavonoid components extracted from"	( Therapeutic Effect of Icaritin on Cerebral Ischemia-Reperfusion-Induced Senescence and Apoptosis in an Acute Ischemic Stroke Mouse Model. Chen, CM; Chen, MC; Guan, SS; Liu, SH; Wu, CT; Yang, TH, 2022)	1.76
"Icaritin is a prenylflavonoid present in the Chinese herbal medicinal plant Epimedium spp. "	( Complete biosynthesis of the potential medicine icaritin by engineered Saccharomyces cerevisiae and Escherichia coli. Huang, W; Li, C; Li, X; Wang, J; Wang, P; Wang, Y; Yan, X; Yang, X; Zhang, Y; Zhou, Z, 2021)	2.32
"Icaritin is an aglycone of flavonoid glycosides from Herba Epimedii. "	( Highly efficient bioconversion of icariin to icaritin by whole-cell catalysis. Chen, WW; Ding, B; Du, LQ; Guo, M; Huang, RB; Liang, M; Lin, Y; Pang, H; Wei, YT, 2023)	2.61
"Icaritin (ICT) is a natural compound extracted from anti-osteoporosis herb"	( Icaritin ameliorates RANKL-mediated osteoclastogenesis and ovariectomy-induced osteoporosis. Chen, K; Huang, JM; Jiang, AL; Lai, Q; Qi, GB; Wang, XH; Wang, Z; Zhang, YQ, 2023)	3.07
"Icaritin (ICT) is a traditional Chinese herbal medicine that exhibits antitumor efficacy in variety of cancers including PCa."	( Anticancer effect of icaritin on prostate cancer via regulating miR-381-3p and its target gene UBE2C. Ding, Q; Hu, J; Hu, M; Jiang, H; Ma, C; Rashid, K; Wu, X; Yang, C, 2019)	1.55
"Icaritin is a promising anti-hepatoma drug that is currently being tested in a phase-III clinical trial. "	( Preparation, Characterization, and In Vivo Evaluation of Amorphous Icaritin Nanoparticles Prepared by a Reactive Precipitation Technique. Chen, X; Jin, M; Kong, J; Li, F; Liang, H; Meng, K; Tang, C; Yao, H; Yin, H; Yuan, Q, 2021)	2.3
"1. Icaritin is a natural flavonoid with anti-osteoporosis activity. "	( Glucuronidation of icaritin by human liver microsomes, human intestine microsomes and expressed UDP-glucuronosyltransferase enzymes: identification of UGT1A3, 1A9 and 2B7 as the main contributing enzymes. Dai, Y; Gonzalez, FJ; Hong, X; Qin, Z; Wang, L; Wu, B; Yao, X; Yao, Z; Zhao, G, 2018)	1.43
"Icaritin is a compound extracted from herb, recent study have found it is able to influence the activity of various types of cancer. "	( Effects of Icaritin on the physiological activities of esophageal cancer stem cells. Chen, M; Dong, X; Gou, Y; Han, S; Jin, D; Ma, J, 2018)	2.31
"Icaritin (ICT) is a hydrolytic form of icariin isolated from plants of the genus Epimedium. "	( Icaritin synergistically enhances the radiosensitivity of 4T1 breast cancer cells. Chen, C; Han, D; Hong, J; Li, S; Lv, W; Yang, S; Zhang, L; Zhang, M; Zhang, W; Zhang, Z, 2013)	3.28
"Icaritin (ICT) is a hydrolytic product of Icariin."	( Icaritin attenuates cigarette smoke-mediated oxidative stress in human lung epithelial cells via activation of PI3K-AKT and Nrf2 signaling. Dong, J; Wong, PF; Wu, J; Xia, S; Xu, H; Xu, J, 2014)	2.57
"Icaritin (ICT) is a major bioactive prenylflavonoid derivative contained in the Epimedium which is a widely used herbal medicine for the treatment of infertility, impotence, cardiovascular and skeletal diseases listed in the Chinese Pharmacopoeia. "	( Biodistribution evaluation of icaritin in rats by ultra-performance liquid chromatography-tandem mass spectrometry. Zhang, SQ, 2014)	2.13
"Icaritin is an active ingredient derived from the plant Herba epimedium, which exhibits various pharmacological and biological activities. "	( Anticancer agent icaritin induces apoptosis through caspase-dependent pathways in human hepatocellular carcinoma cells. Gong, L; Peng, Q; Qu, L; Si, J; Sun, L, 2015)	2.2
"Icaritin is an active prenylflavonoid derived from Epimedium genus, a traditional Chinese medicine. "	( Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3. Dai, C; Deng, M; Li, R; Li, Z; Liu, S; Luo, Y; Peng, H; Wang, Z; Xu, Y; Zhang, G; Zhu, S, 2015)	3.3
"Icaritin (ICT) is a traditional Chinese medicinal herb proved to be neuroprotective and exerts promoting effects on cardiac differentiation. "	( Icaritin Attenuates Myocardial Ischemia and Reperfusion Injury Via Anti-Inflammatory and Anti-Oxidative Stress Effects in Rats. Shi, J; Xing, B; Yang, L; Zhang, W; Zhou, X, 2015)	3.3
"Icaritin (ICT) is an active monomer extracted from Chinese herbals named the Epimedium genus."	( The role of icaritin in regulating Foxp3/IL17a balance in systemic lupus erythematosus and its effects on the treatment of MRL/lpr mice. Chan, TM; Dai, Y; Li, D; Liao, J; Liu, Y; Long, H; Lu, Q; Tan, Y; Wu, H; Yung, S; Zhao, M, 2016)	1.53
"Icaritin (IT) is a flavonoid isolated from Herba Epimedii. "	( Iciartin, a novel FASN inhibitor, exerts anti-melanoma activities through IGF-1R/STAT3 signaling. Cao, H; Du, J; Fu, X; Li, T; Liu, B; Su, T; Tse, AK; Wu, J; Xu, J; Yu, ZL, 2016)	1.88
"Icaritin (ICT) is a prenyl flavonoid derived from the Epimedium genus, which has many biological and pharmacological effects."	( Antitumoral action of icaritin in LNCaP prostate cancer cells by regulating PEA3/HER2/AR signaling. Hu, J; Hu, M; Jiang, H; Mao, S; Wei, B; Wen, H; Xu, H; Yang, T; Zhu, W, 2016)	1.47
"Icaritin is an active ingredient extracted from the plant Herba Epimedium Sagittatum (Sieb. "	( Icaritin induces cell death in activated hepatic stellate cells through mitochondrial activated apoptosis and ameliorates the development of liver fibrosis in rats. Cao, L; Li, J; Liao, J; Liu, P; Qian, H; Wu, M; Xu, W; Yin, Z; Zhang, R, 2011)	3.25
"Icaritin is a native compound from Epimedium Genus, a traditional Chinese herbal medicine which is effective in treating asthma, autoimmune diseases and viral infections. "	( Icaritin inhibits T cell activation and prolongs skin allograft survival in mice. He, L; Hu, Y; Li, X; Liu, S; Wang, S; Zhou, H, 2012)	3.26
"Icaritin (ICT) is a main aglycone and also active intestinal metabolite of prenylflavonoids from the Chinese medicine Herba Epimedii. "	( Oral absorption and excretion of icaritin, an aglycone and also active metabolite of prenylflavonoids from the Chinese medicine Herba Epimedii in rats. Chang, Q; Li, Y; Wang, GN; You, C; Zhang, L; Zheng, Y, 2012)	2.1

Excerpt	Reference	Relevance
"Icaritin has a wide range of pharmacological activities, including significant an-titumor activity. "	( Icaritin inhibits endometrial carcinoma cells by suppressing O-GlcNAcylation of FOXC1. Kong, Y; Liu, Y; Wang, G; Wang, Y; Yang, F; Zhang, H, 2023)	3.8
"Icaritin has a wide range of pharmacological and biological activities, including cardiovascular function improvement, hormone regulation and antitumor activity."	( Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3. Dai, C; Deng, M; Li, R; Li, Z; Liu, S; Luo, Y; Peng, H; Wang, Z; Xu, Y; Zhang, G; Zhu, S, 2015)	2.58
"Icaritin has potential anticancer effects on various cancers, including multiple myeloma (MM). "	( Icaritin-elevated circ_0000190 suppresses the malignant progression of multiple myeloma by targeting miR-301a. Chai, J; Zhang, Q; Zhang, XR; Zhu, YH, 2022)	3.61
"Icaritin (ICT) has been previously demonstrated to display protective effects against cerebral ischemic reperfusion (I/R) by inhibiting oxidative stress, but the mechanism remains unclear. "	( UHPLC-ESI-QE-Orbitrap-MS based metabolomics reveals the antioxidant mechanism of icaritin on mice with cerebral ischemic reperfusion. Feng, Z; Liu, Z; Sun, C; Sun, L; Tang, Y; Yao, J; Zhang, G; Zhao, Y, 2023)	2.58
"Icaritin has a wide range of pharmacological activities, including significant an-titumor activity. "	( Icaritin inhibits endometrial carcinoma cells by suppressing O-GlcNAcylation of FOXC1. Kong, Y; Liu, Y; Wang, G; Wang, Y; Yang, F; Zhang, H, 2023)	3.8
"Icaritin has a wide range of pharmacological and biological activities, including cardiovascular function improvement, hormone regulation and antitumor activity."	( Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3. Dai, C; Deng, M; Li, R; Li, Z; Liu, S; Luo, Y; Peng, H; Wang, Z; Xu, Y; Zhang, G; Zhu, S, 2015)	2.58
"Icaritin has selective estrogen receptor (ER) modulating activity. "	( Icaritin induces growth inhibition and apoptosis of human prostatic smooth muscle cells in an estrogen receptor-independent manner. Chen, MF; Dai, YQ; Li, Y; Qi, L; Zhang, P; Zu, XB, 2010)	3.25

Excerpt	Reference	Relevance
"Icaritin can enhance radiosensitivity of NPC cells both "	( [Icaritin increases radiosensitivity of nasopharyngeal carcinoma cells by regulating iron death]. Gou, W; Hou, W; Hu, T; Li, Y; Liu, G; Ren, Z; Zuo, D, 2023)	3.26
"Icaritin can inhibit cell proliferation and induce apoptosis in Oral Squamous Cell Carcinoma (OSCC). "	( Stable Loading and Delivery of Icaritin Using PEG-PCL Micelles for Effective Treatment of Oral Squamous Cell Carcinoma. Chen, XJ; Yang, JG; Zhang, J; Zhou, G, 2021)	2.35
"Icaritin can inhibit cell proliferation and induce apoptosis of KM3/BTZ cells, moreover, can effectively reverse the multidrug resistance of KM3/BTZ cells. "	( [Icaritin Reverses Multidrug Resistance of Multiple Myeloma Cell Line KM3/BTZ]. Chen, X; Fang, J; Fang, ZQ; Huang, XR; Li, ZJ; Li, ZY; Zhang, JG, 2017)	2.81
"Icaritin promotes platelet production and regulates T cell polarization, but its mechanism is not clear."	( Icaritin Provokes Serum Thrombopoietin and Downregulates Thrombopoietin/MPL of the Bone Marrow in a Mouse Model of Immune Thrombocytopenia. Dai, Z; Liu, R; Liu, X; Pu, X; Sun, Y; Tian, F; Zhang, K; Zhao, X, 2018)	2.64
"Icaritin can inhibit proliferation and induce apoptosis of THP-1 in vitro, Icaritin may induce apoptosis in THP-1 cells through the mitochondrial pathway."	( [Effect of Icaritin on Proliferation and Apoptosis of THP-1 Cell and Its Mechanism]. Kuang, WY; Li, RJ; Zhang, GS; Zheng, MC, 2017)	2.29
"Icaritin (ICT) displays numerous pharmacological activities for the treatment of various cancers, osteoporosis, inflammation, and angiocardiopathy. "	( Oral absorption, distribution, metabolism, and excretion of icaritin in rats by Q-TOF and UHPLC-MS/MS. Zhang, SQ; Zhang, SZ, 2017)	2.14

Excerpt	Reference	Relevance
"Icaritin treatment caused a rapid increase in ROS in HeLa and SiHa cells, which was followed by a prominent increase in the number of DNA strand breaks."	( Reactive oxygen species induced by icaritin promote DNA strand breaks and apoptosis in human cervical cancer cells. Chen, X; Hou, Y; Li, F; Song, L, 2019)	1.51
"Icaritin treatment induced immune biomarkers and immune-modulating activities in myeloid cells were also explored."	( First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers. Ding, X; Fan, Y; Hao, R; Jiang, J; Li, S; Li, Y; Liu, K; Meng, K; Qiu, W; Wang, S; Xu, B; Ye, B; Yue, J; Zhao, H; Zheng, L, 2019)	1.49
"Icaritin treatment induced changes in immune biomarkers-and immune-suppressive myeloid cells were observed."	( First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers. Ding, X; Fan, Y; Hao, R; Jiang, J; Li, S; Li, Y; Liu, K; Meng, K; Qiu, W; Wang, S; Xu, B; Ye, B; Yue, J; Zhao, H; Zheng, L, 2019)	1.49
"Icaritin pretreatment significantly inhibited the elevation of intracellular Ca(2+) induced by LPS."	( Icaritin exhibits anti-inflammatory effects in the mouse peritoneal macrophages and peritonitis model. Huang, X; Lai, X; Sun, C; Tang, X; Ye, Y; Yin, P; Zeng, X; Zeng, Y, 2013)	2.55
"Icaritin treatment also induced expression of pro-apoptotic protein Bax with a concomitant decrease of Bcl-2 expression."	( Icaritin causes sustained ERK1/2 activation and induces apoptosis in human endometrial cancer cells. Fu, XQ; Hou, Y; Huang, X; Qi, ST; Sheng, J; Sun, QY; Tong, JS; Wang, YP; Zhang, QH, 2011)	2.53
"Treatment of icaritin in both primary and established (HT-29) CRC cells induced feedback activation of autophagy, evidenced by p62 degradation, Beclin-1 and autophagy-related gene-5 (ATG-5) upregulation, as well as light chain 3B (LC3B)-GFP puncta formation."	( AMPK-autophagy inhibition sensitizes icaritin-induced anti-colorectal cancer cell activity. Chen, MB; Dong, D; Gu, J; Xu, D; Yang, Q; Zhang, G; Zhou, C, 2017)	1.08
"When treated with icaritin for 24 to 72 h, cell growth was strongly inhibited (at 48 h IC(50) was 10.74+/-1.59 micromol/l, P<0.001) companied with a mitochondrial transmembrane potential (_Psim) drop."	( A novel anticancer agent, icaritin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells. Huang, X; Lou, Y; Zhu, D, 2007)	0.96

Excerpt	Reference	Relevance
"No drug-related adverse events ≥ Grade 3 were observed in all 20 enrolled HCC patients."	( First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers. Ding, X; Fan, Y; Hao, R; Jiang, J; Li, S; Li, Y; Liu, K; Meng, K; Qiu, W; Wang, S; Xu, B; Ye, B; Yue, J; Zhao, H; Zheng, L, 2019)	0.77

Excerpt	Reference	Relevance
"This study successfully elucidated the pharmacokinetic profiles of EWH extract and five EWH-derived prenylflavonoid monomers in rats."	( Systematic considerations for a multicomponent pharmacokinetic study of Epimedii wushanensis herba: From method establishment to pharmacokinetic marker selection. Jin, Y; Wang, C; Wu, C; Zhang, J, 2015)	0.42
"The study was a comprehensive analysis of metabolic pathways and pharmacokinetic markers."	( Systematic considerations for a multicomponent pharmacokinetic study of Epimedii wushanensis herba: From method establishment to pharmacokinetic marker selection. Jin, Y; Wang, C; Wu, C; Zhang, J, 2015)	0.42
" To select appropriate EWH-derived pharmacokinetic markers, a high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was established to simultaneously monitor 14 major compounds in unhydrolyzed plasma and 10 potential pharmacokinetic markers in hydrolyzed plasma."	( Systematic considerations for a multicomponent pharmacokinetic study of Epimedii wushanensis herba: From method establishment to pharmacokinetic marker selection. Jin, Y; Wang, C; Wu, C; Zhang, J, 2015)	0.42
"The pharmacokinetic profiles indicated that the glucuronide conjugates of icaritin were the principle circulating metabolites and that total icaritin accounted for ∼99% of prenylflavonoid exposure after administration of EWH-derived materials to rats."	( Systematic considerations for a multicomponent pharmacokinetic study of Epimedii wushanensis herba: From method establishment to pharmacokinetic marker selection. Jin, Y; Wang, C; Wu, C; Zhang, J, 2015)	0.65
"Icaritin in hydrolyzed plasma can be used as a pharmacokinetic marker to reflect prenylflavonoid exposure levels, as well as the changes over time of its glucuronide conjugates."	( Systematic considerations for a multicomponent pharmacokinetic study of Epimedii wushanensis herba: From method establishment to pharmacokinetic marker selection. Jin, Y; Wang, C; Wu, C; Zhang, J, 2015)	1.86

Excerpt	Reference	Relevance
" In order to examine their bioavailability in humans, we have developed and validated a sensitive method to quantify icaritin and desmethylicaritin in human sera, using gas chromatography-mass spectrometry."	( Sensitive and rapid method to quantify icaritin and desmethylicaritin in human serum using gas chromatography-mass spectrometry. Shen, P; Wong, SP; Yong, EL, 2007)	0.82
" The oral bioavailability of ICT was 35% of dose, estimated by its total plasma drug concentrations."	( Oral absorption and excretion of icaritin, an aglycone and also active metabolite of prenylflavonoids from the Chinese medicine Herba Epimedii in rats. Chang, Q; Li, Y; Wang, GN; You, C; Zhang, L; Zheng, Y, 2012)	0.66
" However, its low bioavailability limits its clinical efficacy for the treatment of osteoporosis."	( Mechanism of enhanced antiosteoporosis effect of circinal-icaritin by self-assembled nanomicelles in vivo with suet oil and sodium deoxycholate. Feng, L; Jia, X; Jiang, J; Li, J; Sun, E; Zhang, Z, 2015)	0.66
"In this paper, suet oil (SO) was used to improve the oral bioavailability of CIT and enhance its antiosteoporosis effect and absorption."	( Mechanism of enhanced antiosteoporosis effect of circinal-icaritin by self-assembled nanomicelles in vivo with suet oil and sodium deoxycholate. Feng, L; Jia, X; Jiang, J; Li, J; Sun, E; Zhang, Z, 2015)	0.66
"The increased antiosteoporosis effects and bioavailability of CIT-SO-DOC self-assembled nanomicelles were due to an increase in absorption of CIT by reducing the particle sizes of CIT."	( Mechanism of enhanced antiosteoporosis effect of circinal-icaritin by self-assembled nanomicelles in vivo with suet oil and sodium deoxycholate. Feng, L; Jia, X; Jiang, J; Li, J; Sun, E; Zhang, Z, 2015)	0.66
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" A novel combination of amorphization and nanonization was used to enhance the oral bioavailability of icaritin."	( Preparation, Characterization, and In Vivo Evaluation of Amorphous Icaritin Nanoparticles Prepared by a Reactive Precipitation Technique. Chen, X; Jin, M; Kong, J; Li, F; Liang, H; Meng, K; Tang, C; Yao, H; Yin, H; Yuan, Q, 2021)	1.07
" IC-MEs significantly improve the bioavailability of IC due to the encapsulation of coix oil-based microemulsion and also obtain the desired liver accumulation and elimination."	( An icaritin-loaded microemulsion based on coix oil for improved pharmacokinetics and enhanced antitumor efficacy. Chen, Y; Li, X; Liu, Y; Qu, D; Zeng, H, 2022)	1.34

Excerpt	Relevance	Reference
"Take conversion rate as index, the effects of pH, temperature, reaction time, dosage of enzyme, concentration of Icariin and metal ion on hydrolysis were studied by single-factor designs and a L9 (3(4)) orthogonal design."	( [Study on preparation of icaritin by enzymolysis of icariin with snail hydrolase]. Chen, L; Jia, D; Jia, X; Shi, F; Sun, E; Xue, J; Zhang, Z, 2010)	0.66
" However, one of the main disadvantages of the compound is the high volume and dosage during long-term administration period."	( The beneficial effect of icaritin on osteoporotic bone is dependent on the treatment initiation timing in adult ovariectomized rats. Bakker, AJ; Guo, B; He, Y; Hung, L; Leung, WN; Pan, X; Peng, S; Qin, L; Zhang, BT; Zhang, G; Zhen, W, 2013)	0.69
" The relative bioavailabilities of CIT-SO high dosage, CIT-SO medium dosage, and CIT-SO low dosage (area under concentration-time curve [AUC]0-∞) compared with that of raw CIT high dosage, CIT medium dosage, and CIT low dosage (AUC0-∞) were 127%, 121%, and 134%, respectively."	( Mechanism of enhanced antiosteoporosis effect of circinal-icaritin by self-assembled nanomicelles in vivo with suet oil and sodium deoxycholate. Feng, L; Jia, X; Jiang, J; Li, J; Sun, E; Zhang, Z, 2015)	0.66
" Meanwhile, mice in negative control group were treated with the same dosage of PBS."	( [Icaritin prevents vascular calcification in mice]. Hua, Q; Ren, L; Tang, S; Wang, Z; Xie, H, 2019)	1.42

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
EWS/FLI fusion protein	Homo sapiens (human)	Potency	22.5328	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Lysine-specific histone demethylase 1A	Homo sapiens (human)	IC50 (µMol)	64.4900	0.0031	2.1602	9.6000	AID1515260
cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)	IC50 (µMol)	2.2000	0.0000	1.1843	9.6140	AID362785
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
regulation of double-strand break repair via homologous recombination	Lysine-specific histone demethylase 1A	Homo sapiens (human)
positive regulation of protein ubiquitination	Lysine-specific histone demethylase 1A	Homo sapiens (human)
regulation of protein localization	Lysine-specific histone demethylase 1A	Homo sapiens (human)
cellular response to UV	Lysine-specific histone demethylase 1A	Homo sapiens (human)
cellular response to gamma radiation	Lysine-specific histone demethylase 1A	Homo sapiens (human)
DNA repair-dependent chromatin remodeling	Lysine-specific histone demethylase 1A	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Lysine-specific histone demethylase 1A	Homo sapiens (human)
positive regulation of neuroblast proliferation	Lysine-specific histone demethylase 1A	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Lysine-specific histone demethylase 1A	Homo sapiens (human)
protein demethylation	Lysine-specific histone demethylase 1A	Homo sapiens (human)
positive regulation of epithelial to mesenchymal transition	Lysine-specific histone demethylase 1A	Homo sapiens (human)
positive regulation of neuron projection development	Lysine-specific histone demethylase 1A	Homo sapiens (human)
cerebral cortex development	Lysine-specific histone demethylase 1A	Homo sapiens (human)
negative regulation of protein binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
neuron maturation	Lysine-specific histone demethylase 1A	Homo sapiens (human)
negative regulation of DNA binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
negative regulation of DNA-binding transcription factor activity	Lysine-specific histone demethylase 1A	Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediator	Lysine-specific histone demethylase 1A	Homo sapiens (human)
positive regulation of cell size	Lysine-specific histone demethylase 1A	Homo sapiens (human)
negative regulation of DNA-templated transcription	Lysine-specific histone demethylase 1A	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Lysine-specific histone demethylase 1A	Homo sapiens (human)
guanine metabolic process	Lysine-specific histone demethylase 1A	Homo sapiens (human)
muscle cell development	Lysine-specific histone demethylase 1A	Homo sapiens (human)
regulation of androgen receptor signaling pathway	Lysine-specific histone demethylase 1A	Homo sapiens (human)
response to fungicide	Lysine-specific histone demethylase 1A	Homo sapiens (human)
cellular response to cAMP	Lysine-specific histone demethylase 1A	Homo sapiens (human)
regulation of DNA methylation-dependent heterochromatin formation	Lysine-specific histone demethylase 1A	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Lysine-specific histone demethylase 1A	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Lysine-specific histone demethylase 1A	Homo sapiens (human)
positive regulation of neural precursor cell proliferation	Lysine-specific histone demethylase 1A	Homo sapiens (human)
positive regulation of stem cell proliferation	Lysine-specific histone demethylase 1A	Homo sapiens (human)
chromatin remodeling	Lysine-specific histone demethylase 1A	Homo sapiens (human)
positive regulation of cardiac muscle hypertrophy	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
regulation of nitric oxide mediated signal transduction	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
T cell proliferation	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
negative regulation of T cell proliferation	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cGMP catabolic process	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
oocyte development	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
negative regulation of cardiac muscle contraction	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
relaxation of cardiac muscle	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
positive regulation of oocyte development	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cAMP-mediated signaling	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
telomeric DNA binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
p53 binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
chromatin binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
transcription coactivator activity	Lysine-specific histone demethylase 1A	Homo sapiens (human)
protein binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
oxidoreductase activity	Lysine-specific histone demethylase 1A	Homo sapiens (human)
enzyme binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
nuclear receptor coactivator activity	Lysine-specific histone demethylase 1A	Homo sapiens (human)
demethylase activity	Lysine-specific histone demethylase 1A	Homo sapiens (human)
histone demethylase activity	Lysine-specific histone demethylase 1A	Homo sapiens (human)
histone H3K4 demethylase activity	Lysine-specific histone demethylase 1A	Homo sapiens (human)
histone H3K9 demethylase activity	Lysine-specific histone demethylase 1A	Homo sapiens (human)
identical protein binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
MRF binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
flavin adenine dinucleotide binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
nuclear androgen receptor binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
telomeric repeat-containing RNA binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
DNA-binding transcription factor binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
FAD-dependent H3K4me/H3K4me3 demethylase activity	Lysine-specific histone demethylase 1A	Homo sapiens (human)
promoter-specific chromatin binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
transcription factor binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activity	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
protein binding	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cGMP binding	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
metal ion binding	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
chromatin	Lysine-specific histone demethylase 1A	Homo sapiens (human)
nucleus	Lysine-specific histone demethylase 1A	Homo sapiens (human)
chromosome, telomeric region	Lysine-specific histone demethylase 1A	Homo sapiens (human)
nucleus	Lysine-specific histone demethylase 1A	Homo sapiens (human)
nucleoplasm	Lysine-specific histone demethylase 1A	Homo sapiens (human)
transcription regulator complex	Lysine-specific histone demethylase 1A	Homo sapiens (human)
protein-containing complex	Lysine-specific histone demethylase 1A	Homo sapiens (human)
DNA repair complex	Lysine-specific histone demethylase 1A	Homo sapiens (human)
cellular_component	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
cytosol	cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (78)

Assay ID	Title	Year	Journal	Article
AID1445698	Antibacterial activity against Bacillus cereus ATCC 11778 after 24 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1445704	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 29737 after 24 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1445710	Antibacterial activity against methicillin-resistant Staphylococcus aureus BAA-38 after 24 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID362788	Inhibition of human PDE6C at 10 uM	2008	Journal of natural products, Sep, Volume: 71, Issue:9	Potent inhibition of human phosphodiesterase-5 by icariin derivatives.
AID1233700	Cytotoxicity against human MCF7 cells assessed as cell viability by MTT assay	2015	European journal of medicinal chemistry, Jul-15, Volume: 100	Synthesis and cancer cell growth inhibitory activity of icaritin derivatives.
AID1445722	Ratio of HC50 for New Zealand white rabbit RBC to MIC for methicillin-resistant Staphylococcus aureus ATCC BAA-38	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1445733	Membrane permeabilization activity in DOPE/DOPG large unilamellar liposomes assessed as leakage of calcein at 1:4 to 1:8 compound to lipid ratio by fluorescence assay	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1445708	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 after 24 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1256913	Inhibition of human IDH1 expressed in IPTG-induced Escherichia coli BL21 cells assessed as reduction of NADP+ to NADPH after 5 mins by spectrophotometry	2015	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23	Discovery of α-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1.
AID1445706	Antibacterial activity against methicillin-resistant Staphylococcus aureus DB68004 after 24 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID671762	Inhibition of HCV NS3 helicase overexpressed in Escherichia coli BL21(DE3) assessed as inhibition of DNA unwinding activity at 10 uM by FRET assay	2012	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12	Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13.
AID1445714	Ratio of HC50 for New Zealand white rabbit RBC to MIC for methicillin-sensitive Staphylococcus aureus ATCC 29213	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1515260	Inhibition of LSD1 (unknown origin) by fluorescence assay	2019	Bioorganic & medicinal chemistry, 01-15, Volume: 27, Issue:2	Flavone-based natural product agents as new lysine-specific demethylase 1 inhibitors exhibiting cytotoxicity against breast cancer cells in vitro.
AID1445696	Antibacterial activity against Staphylococcus aureus DM4001R after 24 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1256912	Inhibition of human IDH1 R132H mutant expressed in IPTG-induced Escherichia coli BL21 cells assessed as oxidation of NADPH to NADP+ after 5 mins by spectrophotometry	2015	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23	Discovery of α-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1.
AID1445702	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 29213 after 24 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1233702	Cytotoxicity against human A549 cells assessed as cell viability by MTT assay	2015	European journal of medicinal chemistry, Jul-15, Volume: 100	Synthesis and cancer cell growth inhibitory activity of icaritin derivatives.
AID1233701	Cytotoxicity against human MDA-MB-435S cells assessed as cell viability by MTT assay	2015	European journal of medicinal chemistry, Jul-15, Volume: 100	Synthesis and cancer cell growth inhibitory activity of icaritin derivatives.
AID671764	Inhibition of HCV NS3 helicase ATP hydrolysis activity overexpressed in Escherichia coli BL21(DE3) assessed as inhibition of inorganic phosphate release by AM/MG-based colometric analysis in the presence of M13 ssDNA	2012	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12	Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13.
AID1445697	Antibacterial activity against methicillin-resistant Staphylococcus aureus DM 21455 after 24 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1445707	Antibacterial activity against methicillin-resistant Staphylococcus aureus DB57964 after 24 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1445711	Ratio of HC50 for New Zealand white rabbit RBC to MIC for methicillin-sensitive Staphylococcus aureus DM4583R	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1445716	Ratio of HC50 for New Zealand white rabbit RBC to MIC for methicillin-sensitive Staphylococcus aureus ATCC 29737	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID362785	Inhibition of human recombinant PDE5A1 expressed in COS7 cells	2008	Journal of natural products, Sep, Volume: 71, Issue:9	Potent inhibition of human phosphodiesterase-5 by icariin derivatives.
AID1445719	Ratio of HC50 for New Zealand white rabbit RBC to MIC for methicillin-resistant Staphylococcus aureus DB57964	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1445699	Antibacterial activity against methicillin-sensitive Staphylococcus aureus DM4583R after 24 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID428313	Reversal of P-gp-mediated multidrug resistance in human MCF7 cells assessed as assessed as increase in intracellular adriamycin accumulation at 5 uM incubated 2 hrs before adriamycin challenge by spectrophotometry	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Synthesis and antimultidrug resistance evaluation of icariin and its derivatives.
AID1445703	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 6538 after 24 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1445721	Ratio of HC50 for New Zealand white rabbit RBC to MIC for methicillin-resistant Staphylococcus aureus ATCC 700699	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1445701	Antibacterial activity against methicillin-sensitive Staphylococcus aureus DM4299 after 24 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1445709	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 700699 after 24 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1445705	Antibacterial activity against methicillin-resistant Staphylococcus aureus DB6506 after 24 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1445718	Ratio of HC50 for New Zealand white rabbit RBC to MIC for methicillin-resistant Staphylococcus aureus DB68004	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1445713	Ratio of HC50 for New Zealand white rabbit RBC to MIC for methicillin-sensitive Staphylococcus aureus DM4299	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1445717	Ratio of HC50 for New Zealand white rabbit RBC to MIC for methicillin-resistant Staphylococcus aureus DB6506	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1445715	Ratio of HC50 for New Zealand white rabbit RBC to MIC for methicillin-sensitive Staphylococcus aureus ATCC 6538	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID428319	Inhibition of P-gp in human Caco-2 cells assessed as decrease in efflux permeability from basolateral to apical side at 50 uM after 120 mins	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Synthesis and antimultidrug resistance evaluation of icariin and its derivatives.
AID1445712	Ratio of HC50 for New Zealand white rabbit RBC to MIC for methicillin-sensitive Staphylococcus aureus DM4400R	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1445730	Induction of plasma membrane permeability in methicillin-resistant Staphylococcus aureus DM9808R assessed as increase in fluorescence intensity at 12.5 ug/ml measured every 1 sec for 50 mins by SYTOX green dye based fluorimetric assay	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1445700	Antibacterial activity against methicillin-sensitive Staphylococcus aureus DM4400R after 24 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1445695	Antibacterial activity against methicillin-resistant Staphylococcus aureus DM 9808R after 24 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID1233703	Cytotoxicity against African green monkey Vero cells assessed as cell viability by MTT assay	2015	European journal of medicinal chemistry, Jul-15, Volume: 100	Synthesis and cancer cell growth inhibitory activity of icaritin derivatives.
AID428318	Inhibition of P-gp in human Caco-2 cells assessed as increase in influx permeability from apical to basolateral side at 50 uM after 120 mins	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Synthesis and antimultidrug resistance evaluation of icariin and its derivatives.
AID1774205	Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	2021	Journal of medicinal chemistry, 10-28, Volume: 64, Issue:20	Design, Synthesis, and Biological Evaluation of Icaritin Derivatives as Novel Putative DEPTOR Inhibitors for Multiple Myeloma Treatment.
AID1445720	Ratio of HC50 for New Zealand white rabbit RBC to MIC for methicillin-resistant Staphylococcus aureus ATCC 43300	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
AID671761	Inhibition of SARS coronavirus nsP13 helicase activity expressed in Escherichia coli Rosetta assessed inhibition of DNA unwinding activity at 10 uM by FRET assay	2012	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12	Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	17 (8.46)	29.6817
2010's	123 (61.19)	24.3611
2020's	61 (30.35)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (0.50%)	5.53%
Reviews	5 (2.48%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	196 (97.03%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.	2.6	1	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
chlorine chloride : A halide anion formed when chlorine picks up an electron to form an an anion.	2.21	1	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
gallic acid gallate : A trihydroxybenzoate that is the conjugate base of gallic acid.	2.49	2	trihydroxybenzoic acid	antineoplastic agent; antioxidant; apoptosis inducer; astringent; cyclooxygenase 2 inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; geroprotector; human xenobiotic metabolite; plant metabolite
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	3.49	7	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
taurine [no description available]	2.6	1	amino sulfonic acid; zwitterion	antioxidant; Escherichia coli metabolite; glycine receptor agonist; human metabolite; mouse metabolite; nutrient; radical scavenger; Saccharomyces cerevisiae metabolite
chlorzoxazone Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202). chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.	2.1	1	1,3-benzoxazoles; heteroaryl hydroxy compound; organochlorine compound	muscle relaxant; sedative
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	2.05	1	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.17	1	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
midazolam Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.	2.1	1	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
norfloxacin Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.	2.15	1	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug; DNA synthesis inhibitor; environmental contaminant; xenobiotic
oxidopamine Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.. oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).	2.41	1	benzenetriol; catecholamine; primary amino compound	drug metabolite; human metabolite; neurotoxin
pd 98059 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.	2.15	1	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
pentobarbital Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	2.21	1	barbiturates	GABAA receptor agonist
phenacetin Saridon: contains phenacetin, caffeine, propyphenazone & pyrithyldione	2.1	1	acetamides; aromatic ether	cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug
gatifloxacin Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.	2.15	1	N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antiinfective agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
tolbutamide Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.	2.1	1	N-sulfonylurea	human metabolite; hypoglycemic agent; insulin secretagogue; potassium channel blocker
hydroxyproline Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.. hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.	2.06	1	4-hydroxyproline; L-alpha-amino acid zwitterion	human metabolite; mouse metabolite; plant metabolite
carbon tetrachloride Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.	7.1	1	chlorocarbon; chloromethanes	hepatotoxic agent; refrigerant
ethinyl estradiol Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.	2.1	1	17-hydroxy steroid; 3-hydroxy steroid; terminal acetylenic compound	xenoestrogen
trifluoroacetic acid Trifluoroacetic Acid: A very strong halogenated derivative of acetic acid. It is used in acid catalyzed reactions, especially those where an ester is cleaved in peptide synthesis.. trifluoroacetic acid : A monocarboxylic acid that is the trifluoro derivative of acetic acid.	2.15	1	fluoroalkanoic acid	human xenobiotic metabolite; NMR chemical shift reference compound; reagent
pentane Pentanes: Five-carbon saturated hydrocarbon group of the methane series. Include isomers and derivatives.. pentane : A straight chain alkane consisting of 5 carbon atoms.	2.41	1	alkane; volatile organic compound	non-polar solvent; refrigerant
pyrazolanthrone pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.	2.05	1	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector
thiazoles [no description available]	2.07	1	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
imperatorin imperatorin: tumor necrosis factor antagonist; furanocoumarin from West African medicinal plant Clausena anisata; structure in Negwer, 5th ed, #3005. imperatorin : A member of the class of psoralens that is psoralen substituted by a prenyloxy group at position 8. Isolated from Angelica dahurica and Angelica koreana, it acts as a acetylcholinesterase inhibitor.	2.49	2	psoralens	EC 3.1.1.7 (acetylcholinesterase) inhibitor; metabolite
oleanolic acid [no description available]	2.49	2	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
hesperidin Hesperidin: A flavanone glycoside found in CITRUS fruit peels.. hesperidin : A disaccharide derivative that consists of hesperetin substituted by a 6-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.	2.21	1	3'-hydroxyflavanones; 4'-methoxyflavanones; dihydroxyflavanone; disaccharide derivative; flavanone glycoside; monomethoxyflavanone; rutinoside	mutagen
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	2.31	1	dialdehyde	biomarker
3-hydroxyflavone 3-hydroxyflavone: structure given in first source. flavonol : A monohydroxyflavone that is the 3-hydroxy derivative of flavone.	2.07	1	flavonols; monohydroxyflavone
vancomycin Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.	2.15	1	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
d-alpha tocopherol Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.	2.25	1	alpha-tocopherol	algal metabolite; antiatherogenic agent; anticoagulant; antioxidant; antiviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunomodulator; micronutrient; nutraceutical; plant metabolite
tranylcypromine Tranylcypromine: A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311). tranylcypromine : A racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).. (1R,2S)-tranylcypromine : A 2-phenylcyclopropan-1-amine that is the (1R,2S)-enantiomer of tranylcypromine.	2.21	1	2-phenylcyclopropan-1-amine
tricalcium phosphate tricalcium phosphate: a form of tricalcium phosphate used as bioceramic bone replacement material; see also records for alpha-tricalcium phosphate, beta-tricalcium phosphate, calcium phosphate; apatitic tricalcium phosphate Ca9(HPO4)(PO4)5(OH) is the calcium orthophosphate leading to beta tricalcium phosphate Ca3(PO4)2 (b-TCP). calcium phosphate : A calcium salt composed of calcium and phosphate/diphosphate ions; present in milk and used for the mineralisation of calcified tissues.	3.18	5	calcium phosphate
rhamnose [no description available]	2.63	2	L-rhamnose
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.69	2	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
epirubicin Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.	7.13	1	aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
ursolic acid [no description available]	2.49	2	hydroxy monocarboxylic acid; pentacyclic triterpenoid	geroprotector; plant metabolite
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	2.07	1	organic bromide salt	colorimetric reagent; dye
betulinic acid [no description available]	2.49	2	hydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-HIV agent; anti-inflammatory agent; antimalarial; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; plant metabolite
baicalin [no description available]	2.21	1	dihydroxyflavone; glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative	antiatherosclerotic agent; antibacterial agent; anticoronaviral agent; antineoplastic agent; antioxidant; cardioprotective agent; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; ferroptosis inhibitor; neuroprotective agent; non-steroidal anti-inflammatory drug; plant metabolite; prodrug
n,n-bis(trimethylsilyl)-2,2,2-trifluoroacetamide [no description available]	2.03	1
hesperetin [no description available]	2.21	1	3'-hydroxyflavanones; 4'-methoxyflavanones; monomethoxyflavanone; trihydroxyflavanone	antineoplastic agent; antioxidant; plant metabolite
alpha-amyrin alpha-amyrin: beta-amyrin is also available; a 5 ring triterpene derived from taraxasterol that differs from beta-amyrin in having the 29-carbon at the 19 position. alpha-amyrin : A pentacyclic triterpenoid that is ursane which contains a double bond between positions 12 and 13 and in which the hydrogen at the 3beta position is substituted by a hydroxy group.	2.49	2	pentacyclic triterpenoid; secondary alcohol
friedelin 3-friedelanone: from the stem bark of Irvingia gabonensis; structure in first source. friedelin : A pentacyclic triterpenoid that is perhydropicene which is substituted by an oxo group at position 3 and by methyl groups at the 4, 4a, 6b, 8a, 11, 11, 12b, and 14a-positions (the 4R,4aS,6aS,6bR,8aR,12aR,12bS,14aS,14bS-enantiomer). It is the major triterpenoid constituent of cork.	2.49	2	cyclic terpene ketone; pentacyclic triterpenoid	anti-inflammatory drug; antipyretic; non-narcotic analgesic; plant metabolite
taraxerol taraxerol: structure. taraxerol : A pentacyclic triterpenoid that is oleanan-3-ol lacking the methyl group at position 14, with an alpha-methyl substituent at position 13 and a double bond between positions 14 and 15.	2.49	2	pentacyclic triterpenoid; secondary alcohol	metabolite
spathulenol [no description available]	2.49	2	carbotricyclic compound; olefinic compound; sesquiterpenoid; tertiary alcohol	anaesthetic; plant metabolite; vasodilator agent; volatile oil component
fulvestrant Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.	2.02	1	17beta-hydroxy steroid; 3-hydroxy steroid; organofluorine compound; sulfoxide	antineoplastic agent; estrogen antagonist; estrogen receptor antagonist
daidzin daidzin: a potent, selective, and reversible inhibitor of human mitochondrial aldehyde dehydrogenase. daidzein 7-O-beta-D-glucoside : A glycosyloxyisoflavone that is daidzein attached to a beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage. It is used in the treatment of alcohol dependency (antidipsotropic).	2.07	1	7-hydroxyisoflavones 7-O-beta-D-glucoside; hydroxyisoflavone; monosaccharide derivative	plant metabolite
quinone methide quinone methide: intermediate in eumelanin biosynthesis; structure given in first source. quinomethane : A methylidenecyclohexadienone, formally derived from a benzoquinone by replacement of one of the quinone oxygens by a methylidene group.	7.21	1	quinomethane
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	2.41	1	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.	2.15	1	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
maprounic acid maprounic acid: from Maprounea africana; structure given in first source. maprounic acid : A pentacyclic triterpenoid isolated from Maprounea africana and has been shown to exhibit inhibitory activity against HIV-1 reverse transcriptase.	2.49	2	hydroxy monocarboxylic acid; pentacyclic triterpenoid	HIV-1 reverse transcriptase inhibitor; plant metabolite
hamaudol hamaudol: intermediate in the synthesis of furanochromones	2.49	2	chromenes
sb 203580 [no description available]	2.15	1	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
scutellarin scutellarin: see scutellarein for aglycone. scutellarin : The glycosyloxyflavone which is the 7-O-glucuronide of scutellarein.	2.49	2	glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone	antineoplastic agent; proteasome inhibitor
6-o-veratroyl catalpol [no description available]	2.49	2
sorafenib [no description available]	3.41	1	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
sitosterol, (3beta)-isomer Sobatum: tradename; active fraction of Solanum trilobatum; reduces side-effects of radiation-induced toxicity. sitosterol : A member of the class of phytosterols that is stigmast-5-ene substituted by a beta-hydroxy group at position 3.	2.49	2	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; C29-steroid; phytosterols; stigmastane sterol	anticholesteremic drug; antioxidant; mouse metabolite; plant metabolite; sterol methyltransferase inhibitor
deoxycholic acid Deoxycholic Acid: A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.. deoxycholic acid : A bile acid that is 5beta-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 12 respectively.	2.11	1	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human blood serum metabolite
4-allyl-2,6-dimethoxyphenol 4-allyl-2,6-dimethoxyphenol: structure in first source. 4-allyl-2,6-dimethoxyphenol : A member of the class of phenols that is phenol substituted by an allyl group at position 4 and methoxy groups at positions 2 and 6 respectively.	2.49	2	dimethoxybenzene; phenols; phenylpropanoid
4-oxy-6-(4-oxybezoyloxy)dauc-8,9-en 4-oxy-6-(4-oxybezoyloxy)dauc-8,9-en: RN given for (3R-(3alpha,3abeta,4beta,8aalpha))-isomer; a natural benzyl ester of a carotyl type azulene sesquiterpenoid; structure in first source	2.04	1
bortezomib [no description available]	2.15	1	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
8-deoxygartanin 8-deoxygartanin: a butyrylcholinesterase inhibitor; isolated from Garcinia mangostana; structure in first source	2.49	2	xanthones
naringenin (S)-naringenin : The (S)-enantiomer of naringenin.	2.76	3	(2S)-flavan-4-one; naringenin	expectorant; plant metabolite
cellulase Cellulase: An endocellulase with specificity for the hydrolysis of 1,4-beta-glucosidic linkages in CELLULOSE, lichenin, and cereal beta-glucans.. beta-cellotriose : A cellotriose with a beta-configuration at the anomeric position.	2.15	1	cellotriose
naringin [no description available]	2.07	1	(2S)-flavan-4-one; 4'-hydroxyflavanones; dihydroxyflavanone; disaccharide derivative; neohesperidoside	anti-inflammatory agent; antineoplastic agent; metabolite
arachidonic acid icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.	2.6	1	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	3.41	1	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
pectins Pectins: High molecular weight polysaccharides present in the cell walls of all plants. Pectins cement cell walls together. They are used as emulsifiers and stabilizers in the food industry. They have been tried for a variety of therapeutic uses including as antidiarrheals, where they are now generally considered ineffective, and in the treatment of hypercholesterolemia.. alpha-D-galacturonic acid : The alpha-anomer of D-galacturonic acid.	2.6	1	D-galactopyranuronic acid
8-isopentenylnaringenin 8-isopentenylnaringenin: a non-steroidal phytoestrogen from Anaxagorea luzonensis; structure in first source	2.04	1	flavanones
cinnamaldehyde 3-phenylprop-2-enal : A member of the class of cinnamaldehydes that is prop-2-enal in which a hydrogen at position 3 has been replaced by a phenyl group. The configuration of the double bond is not specified; the name "cinnamaldehyde" is widely used to refer to the E (trans) isomer.. (E)-cinnamaldehyde : The E (trans) stereoisomer of cinnamaldehyde, the parent of the class of cinnamaldehydes.	2.04	1	3-phenylprop-2-enal; cinnamaldehydes	antifungal agent; EC 4.3.1.24 (phenylalanine ammonia-lyase) inhibitor; flavouring agent; hypoglycemic agent; plant metabolite; sensitiser; vasodilator agent
glycosides [no description available]	2.78	3
isoliquiritigenin [no description available]	2.49	2	chalcones	antineoplastic agent; biological pigment; EC 1.14.18.1 (tyrosinase) inhibitor; GABA modulator; geroprotector; metabolite; NMDA receptor antagonist
tamoxifen [no description available]	2.11	1	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
4,6-dimorpholino-n-(4-nitrophenyl)-1,3,5-triazin-2-amine 4,6-dimorpholino-N-(4-nitrophenyl)-1,3,5-triazin-2-amine: an mTOR activator; structure in first source	2.15	1
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	2.69	2	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
wogonoside wogonoside: from Scutellaria baicalensis; structure in first source. wogonin 7-O-beta-D-glucuronide : The glycosyloxyflavone which is the 7-O-glucuronide of wogonin.	2.21	1	beta-D-glucosiduronic acid; glycosyloxyflavone; monohydroxyflavone; monomethoxyflavone; monosaccharide derivative
ginsenosides ginsenoside : Triterpenoid saponins with a dammarane-like skeleton originally isolated from ginseng (Panax) species. Use of the term has been extended to include semi-synthetic derivatives.	3.41	1
rhodamine 123 Rhodamine 123: A fluorescent probe with low toxicity which is a potent substrate for ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 and the bacterial multidrug efflux transporter. It is used to assess mitochondrial bioenergetics in living cells and to measure the efflux activity of ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 in both normal and malignant cells. (Leukemia 1997;11(7):1124-30). rhodamine 123(1+) : A cationic fluorescent dye derived from 9-phenylxanthene.	2.17	1	organic cation; xanthene dye	fluorochrome
quercetin [no description available]	2.49	2	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
apigenin Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.	2.47	2	trihydroxyflavone	antineoplastic agent; metabolite
luteolin [no description available]	2.11	1	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
linoleic acid Linoleic Acid: A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed). linoleic acid : An octadecadienoic acid in which the two double bonds are at positions 9 and 12 and have Z (cis) stereochemistry.	2.6	1	octadecadienoic acid; omega-6 fatty acid	algal metabolite; Daphnia galeata metabolite; plant metabolite
stigmasterol stigmasta-5,22-dien-3-ol: isolated from freeze-dried powder of Blackberries (Rubus ursinus L.) which showed an activity on inhibition of chemocarcinogen. stigmasterol : A 3beta-sterol that consists of 3beta-hydroxystigmastane having double bonds at the 5,6- and 22,23-positions.	2.49	2	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; phytosterols; stigmastane sterol	plant metabolite
quercetin 3-o-glucopyranoside quercetin 3-O-glucopyranoside: structure in first source. quercetin 3-O-beta-D-glucopyranoside : A quercetin O-glucoside that is quercetin with a beta-D-glucosyl residue attached at position 3. Isolated from Lepisorus contortus, it exhibits antineoplastic activityand has been found to decrease the rate of polymerization and sickling of red blood cells	2.52	2	beta-D-glucoside; monosaccharide derivative; quercetin O-glucoside; tetrahydroxyflavone	antineoplastic agent; antioxidant; antipruritic drug; bone density conservation agent; geroprotector; histamine antagonist; osteogenesis regulator; plant metabolite
rutin Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders.	2.21	1	disaccharide derivative; quercetin O-glucoside; rutinoside; tetrahydroxyflavone	antioxidant; metabolite
kaempferol [no description available]	2.49	2	7-hydroxyflavonol; flavonols; tetrahydroxyflavone	antibacterial agent; geroprotector; human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; plant metabolite
genistein [no description available]	2.03	1	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
cucurbitacin i cucurbitacin I: toxic constituent in edible gourd; see also records for cucurbitacins & specific cucurbitacins. cucurbitacin I : A cucurbitacin that is 9,10,14-trimethyl-4,9-cyclo-9,10-secocholesta-2,5,23-triene substituted by hydroxy groups at positions 2, 16, 20 and 25 and oxo groups at positions 1, 11 and 22.	2.17	1	cucurbitacin; tertiary alpha-hydroxy ketone	antineoplastic agent; plant metabolite
amentoflavone [no description available]	2.07	1	biflavonoid; hydroxyflavone; ring assembly	angiogenesis inhibitor; antiviral agent; cathepsin B inhibitor; P450 inhibitor; plant metabolite
baicalein [no description available]	2.52	2	trihydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; ferroptosis inhibitor; geroprotector; hormone antagonist; plant metabolite; prostaglandin antagonist; radical scavenger
chrysin chrysin : A dihydroxyflavone in which the two hydroxy groups are located at positions 5 and 7.	2.49	2	7-hydroxyflavonol; dihydroxyflavone	anti-inflammatory agent; antineoplastic agent; antioxidant; EC 2.7.11.18 (myosin-light-chain kinase) inhibitor; hepatoprotective agent; plant metabolite
diosmetin [no description available]	2.21	1	3'-hydroxyflavonoid; monomethoxyflavone; trihydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; antioxidant; apoptosis inducer; bone density conservation agent; cardioprotective agent; plant metabolite; tropomyosin-related kinase B receptor agonist; vasodilator agent
diosmin [no description available]	2.21	1	dihydroxyflavanone; disaccharide derivative; glycosyloxyflavone; monomethoxyflavone; rutinoside	anti-inflammatory agent; antioxidant
galangin 5,7-dihydroxyflavonol: antimicrobial from the twigs of Populus nigra x Populus deltoides; structure in first source. galangin : A 7-hydroxyflavonol with additional hydroxy groups at positions 3 and 5 respectively; a growth inhibitor of breast tumor cells.	2.49	2	7-hydroxyflavonol; trihydroxyflavone	antimicrobial agent; EC 3.1.1.3 (triacylglycerol lipase) inhibitor; plant metabolite
gartanin gartanin : A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 3, 5 and 8 and prenyl groups at positions 2 and 4.	2.11	1	polyphenol; xanthones	antineoplastic agent; plant metabolite
hyperoside quercetin 3-O-beta-D-galactopyranoside : A quercetin O-glycoside that is quercetin with a beta-D-galactosyl residue attached at position 3. Isolated from Artemisia capillaris, it exhibits hepatoprotective activity.	2.07	1	beta-D-galactoside; monosaccharide derivative; quercetin O-glycoside; tetrahydroxyflavone	hepatoprotective agent; plant metabolite
mangostin mangostin: xanthone from rind of Garcinia mangostana Linn. fruit. alpha-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3 and 6, a methoxy group at position 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antioxidant, antimicrobial and antitumour activities.	2.49	2	aromatic ether; phenols; xanthones	antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite
myricetin [no description available]	2.49	2	7-hydroxyflavonol; hexahydroxyflavone	antineoplastic agent; antioxidant; cyclooxygenase 1 inhibitor; food component; geroprotector; hypoglycemic agent; plant metabolite
scutellarein scutellarein: aglycone of scutellarin from Scutellaria baicalensis; carthamidin is 2S isomer of scutellarein; do not confuse with isoscutellarein and/or isocarthamidin which are respective regioisomers, or with the scutelarin protein. scutellarein : Flavone substituted with hydroxy groups at C-4', -5, -6 and -7.	2.49	2	tetrahydroxyflavone	metabolite
wogonin wogonin: structure in first source. wogonin : A dihydroxy- and monomethoxy-flavone in which the hydroxy groups are positioned at C-5 and C-7 and the methoxy group is at C-8.	2.21	1	dihydroxyflavone; monomethoxyflavone	angiogenesis inhibitor; antineoplastic agent; cyclooxygenase 2 inhibitor; plant metabolite
coumestrol Coumestrol: A daidzein derivative occurring naturally in forage crops which has some estrogenic activity.. coumestrol : A member of the class of coumestans that is coumestan with hydroxy substituents at positions 3 and 9.	2.1	1	coumestans; delta-lactone; polyphenol	anti-inflammatory agent; antioxidant; plant metabolite
desmethylicaritin desmethylicaritin: structure in first source	3.42	7
icariin [no description available]	5.68	23	flavonols; glycosyloxyflavone	antioxidant; bone density conservation agent; EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; phytoestrogen
sophoricoside sophoricoside: from fruit of Sophora japonica; structure in first source	2.07	1	acrovestone; isoflavonoid
lead Lead: A soft, grayish metal with poisonous salts; atomic number 82, atomic weight 207.2, symbol Pb.	7.21	1	carbon group element atom; elemental lead; metal atom	neurotoxin
gamma-mangostin gamma-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3, 6 and 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antitumour activity.	2.49	2	phenols; xanthones	antineoplastic agent; plant metabolite; protein kinase inhibitor
icarrin icarrin: isolated from Herba epimedii	7.41	1	flavonoids; glycoside
baohuoside i baohuoside I: structure given in first source; isolated from the herb Epimedium davidii	3.35	6	glycosyloxyflavone	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; plant metabolite
beta-Mangostin [no description available]	2.11	1	xanthones
9-Hydroxycalabaxanthone [no description available]	2.11	1	xanthones
lyoniside daucosterol : A steroid saponin that is sitosterol attached to a beta-D-glucopyranosyl residue at position 3 via a glycosidic linkage. It has bee isolated from Panax japonicus var. major and Breynia fruticosa.	2.49	2	beta-D-glucoside; monosaccharide derivative; steroid saponin	plant metabolite
icariside i icariside I: structure in first source	2.45	2
epimedin c epimedin C: structure given in first source; from Epimedium sp.	2.06	1	flavonoids; glycoside
mannich bases Mannich Bases: Ketonic amines prepared from the condensation of a ketone with formaldehyde and ammonia or a primary or secondary amine. A Mannich base can act as the equivalent of an alpha,beta unsaturated ketone in synthesis or can be reduced to form physiologically active amino alcohols.	2.15	1
ginsenoside rb1 [no description available]	2.49	2	ginsenoside; glycoside; tetracyclic triterpenoid	anti-inflammatory drug; anti-obesity agent; apoptosis inhibitor; neuroprotective agent; plant metabolite; radical scavenger
licoflavone c licoflavone C: Antimutagenic Agent; a naturally occurring prenyl-flavone extracted from Genista ephedroides; structure in first source	2.04	1
Diosmetin 7-O-beta-D-glucopyranoside [no description available]	2.55	2	flavonoids; glycoside
verproside verproside: from Pseudolysimachion longifolium; structure in first source	2.49	2	glycoside	metabolite
minecoside [no description available]	2.49	2	hydroxycinnamic acid	metabolite
prim-o-glucosylcimifugin prim-O-glucosylcimifugin: from Peucedanum dissolutum; structure in first source	2.49	2	organic heterotricyclic compound; oxacycle
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	2.15	1
sphingosine kinase [no description available]	7.15	1
gypenoside XVII gypenoside XVII : A ginsenoside found in Panax species that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-S positions, in which the hydroxy groups at positions 3 and 20 have been converted to the corresponding beta-D-glucopyranoside and beta-D-glucopyranosyl-(1->6)-beta-D-glucopyranoside respectively, and in which a double bond has been introduced at the 24-25 position.	2.49	2	12beta-hydroxy steroid; beta-D-glucoside; disaccharide derivative; ginsenoside; tetracyclic triterpenoid	plant metabolite
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	2.9	3
phytoestrogens Phytoestrogens: Compounds derived from plants, primarily ISOFLAVONES that mimic or modulate endogenous estrogens, usually by binding to ESTROGEN RECEPTORS.	2.76	3
cyclin d1 Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.	2.15	1
ganciclovir [no description available]	2.11	1	2-aminopurines; oxopurine	antiinfective agent; antiviral drug
sildenafil sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.	2.04	1	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent

Condition	Indicated	Relationship Strength	Studies	Trials
Impotence [description not available]	0	2.04	1	0
Erectile Dysfunction The inability in the male to have a PENILE ERECTION due to psychological or organ dysfunction.	0	2.04	1	0
Plasmodium falciparum Malaria [description not available]	0	2.1	1	0
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	0	2.1	1	0
Extravascular Hemolysis [description not available]	0	2.15	1	0
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	0	2.15	1	0
Keratitis Inflammation of the cornea.	0	2.15	1	0
Congenital Zika Syndrome [description not available]	0	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	4.11	13	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1	0
Kahler Disease [description not available]	0	4.21	5	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	0	4.21	5	0
Benign Neoplasms [description not available]	0	2.94	3	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	1	4.94	3	0
Dermatoses [description not available]	0	2.41	1	0
Skin Diseases Diseases involving the DERMIS or EPIDERMIS.	0	2.41	1	0
Pain, Chronic [description not available]	0	2.41	1	0
Allodynia [description not available]	0	2.76	2	0
Innate Inflammatory Response [description not available]	0	3.12	4	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	8.12	4	0
Chronic Pain Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.	0	2.41	1	0
Cancer of Stomach [description not available]	0	2.41	1	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	0	2.41	1	0
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	0	2.41	1	0
Malignant Melanoma [description not available]	0	2.91	3	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	0	2.91	3	0
Cerebral Infarction, Middle Cerebral Artery [description not available]	0	2.41	1	0
Apoplexy [description not available]	0	2.41	1	0
Acute Ischemic Stroke [description not available]	0	8.51	5	0
Cerebral Ischemia [description not available]	0	2.9	2	0
Injury, Ischemia-Reperfusion [description not available]	0	3.22	3	0
Ischemic Stroke Stroke due to BRAIN ISCHEMIA resulting in interruption or reduction of blood flow to a part of the brain. When obstruction is due to a BLOOD CLOT formed within in a cerebral blood vessel it is a thrombotic stroke. When obstruction is formed elsewhere and moved to block a cerebral blood vessel (see CEREBRAL EMBOLISM) it is referred to as embolic stroke. Wake-up stroke refers to ischemic stroke occurring during sleep while cryptogenic stroke refers to ischemic stroke of unknown origin.	0	8.51	5	0
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	0	2.9	2	0
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	0	8.22	3	0
Infarction, Middle Cerebral Artery NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.	0	2.41	1	0
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	0	7.41	1	0
Fatty Liver, Nonalcoholic [description not available]	0	2.76	2	0
Non-alcoholic Fatty Liver Disease Fatty liver finding without excessive ALCOHOL CONSUMPTION.	0	7.76	2	0
Anterior Choroidal Artery Infarction [description not available]	0	3.33	4	0
Cerebral Infarction The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).	0	3.33	4	0
Cancer of Liver [description not available]	0	8.23	20	1
Liver Neoplasms Tumors or cancer of the LIVER.	0	8.23	20	1
Breast Cancer [description not available]	0	3.6	8	0
Breast Neoplasms Tumors or cancer of the human BREAST.	1	5.6	8	0
Clinically Isolated CNS Demyelinating Syndrome [description not available]	0	2.6	1	0
Demyelinating Diseases Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.	0	2.6	1	0
Cancer of Endometrium [description not available]	0	2.55	2	0
Endometrial Neoplasms Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.	0	2.55	2	0
Abortion, Recurrent [description not available]	0	3.14	1	0
Abortion, Habitual Three or more consecutive spontaneous abortions.	0	3.14	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	0	3.14	1	0
Bone Loss, Osteoclastic [description not available]	0	2.79	3	0
Age-Related Osteoporosis [description not available]	0	3.53	7	0
Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.	0	3.53	7	0
Nasopharyngeal Carcinoma A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.	0	2.72	2	0
Carcinoma, Anaplastic [description not available]	0	2.52	2	0
Cancer of Nasopharynx [description not available]	0	2.72	2	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	0	2.52	2	0
Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX.	0	2.72	2	0
Hepatocellular Carcinoma [description not available]	0	7.39	14	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	1	9.39	14	1
B16 Melanoma [description not available]	0	2.21	1	0
Cancer of Prostate [description not available]	0	3.36	6	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	0	3.36	6	0
Invasiveness, Neoplasm [description not available]	0	2.82	3	0
Carcinoma, Non-Small Cell Lung [description not available]	0	2.21	1	0
Cancer of Lung [description not available]	0	3.07	4	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	0	2.21	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	0	3.07	4	0
Benign Neoplasms, Brain [description not available]	0	2.61	2	0
Lymph Node Metastasis [description not available]	0	2.25	1	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	0	2.61	2	0
Sclerosis, Systemic [description not available]	0	2.31	1	0
Scleroderma, Systemic A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.	0	2.31	1	0
Carcinoma, Squamous Cell of Head and Neck [description not available]	0	2.61	2	0
Carcinoma, Epidermoid [description not available]	0	2.88	3	0
Cancer of Head [description not available]	0	2.61	2	0
Cancer of Mouth [description not available]	0	2.88	3	0
Squamous Cell Carcinoma of Head and Neck The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.	0	2.61	2	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	0	2.88	3	0
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	0	2.61	2	0
Mouth Neoplasms Tumors or cancer of the MOUTH.	0	2.88	3	0
Experimental Neoplasms [description not available]	0	2.31	1	0
Overweight A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.	0	2.31	1	0
Insulin Sensitivity [description not available]	0	7.31	1	0
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	0	2.31	1	0
Acute Confusional Senile Dementia [description not available]	0	2.41	1	0
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	0	2.41	1	0
Cancer of Ovary [description not available]	0	2.31	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	0	2.31	1	0
Nerve Pain [description not available]	0	2.31	1	0
Neuralgia Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.	0	2.31	1	0
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	0	2.15	1	0
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	0	2.15	1	0
Leucocythaemia [description not available]	0	3.5	2	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	0	3.5	2	0
Aseptic Necrosis of Bone [description not available]	0	3.01	4	0
Osteonecrosis Death of a bone or part of a bone, either atraumatic or posttraumatic.	0	3.01	4	0
Bone Marrow Diseases Diseases involving the BONE MARROW.	0	2.17	1	0
Osteogenic Sarcoma [description not available]	0	3.05	4	0
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	0	3.05	4	0
Astrocytoma, Grade IV [description not available]	0	2.82	3	0
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	0	2.82	3	0
Cancer of Esophagus [description not available]	0	2.17	1	0
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	0	2.17	1	0
Thrombopenia [description not available]	0	2.17	1	0
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	0	7.17	1	0
Cancer of Cervix [description not available]	0	2.21	1	0
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	0	2.21	1	0
Vascular Calcification Deposition of calcium into the blood vessel structures. Excessive calcification of the vessels are associated with ATHEROSCLEROTIC PLAQUES formation particularly after MYOCARDIAL INFARCTION (see MONCKEBERG MEDIAL CALCIFIC SCLEROSIS) and chronic kidney diseases which in turn increase VASCULAR STIFFNESS.	0	7.21	1	0
Hematologic Malignancies [description not available]	0	3.12	1	0
Germinoblastoma [description not available]	0	3.12	1	0
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	0	3.12	1	0
Hematologic Neoplasms Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.	0	3.12	1	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	0	2.08	1	0
Acute Myelogenous Leukemia [description not available]	0	2.08	1	0
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	0	2.08	1	0
Primary Peritonitis [description not available]	0	2.08	1	0
Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.	0	7.08	1	0
Adenocarcinoma Of Kidney [description not available]	0	2.08	1	0
Cancer of Kidney [description not available]	0	2.08	1	0
Angiogenesis, Pathologic [description not available]	0	2.48	2	0
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	0	2.08	1	0
Kidney Neoplasms Tumors or cancers of the KIDNEY.	0	2.08	1	0
Bone Cancer [description not available]	0	2.52	2	0
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	0	2.52	2	0
African Lymphoma [description not available]	0	2.1	1	0
Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.	0	7.1	1	0
Acute Liver Injury, Drug-Induced [description not available]	0	2.1	1	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	0	2.1	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	3.17	5	0
Extranodal NK-T-Cell Lymphoma [description not available]	0	2.11	1	0
Injury, Myocardial Reperfusion [description not available]	0	2.11	1	0
Heart Disease, Ischemic [description not available]	0	2.11	1	0
Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).	0	7.11	1	0
Colorectal Cancer [description not available]	0	2.54	2	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	0	7.13	1	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	0	2.54	2	0
Bladder Cancer [description not available]	0	7.13	1	0
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	0	2.13	1	0
Libman-Sacks Disease [description not available]	0	2.13	1	0
Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.	0	2.13	1	0
Atheroma [description not available]	0	2.13	1	0
Atrophy, Muscle [description not available]	0	2.13	1	0
Muscular Atrophy Derangement in size and number of muscle fibers occurring with aging, reduction in blood supply, or following immobilization, prolonged weightlessness, malnutrition, and particularly in denervation.	0	2.13	1	0
Carcinoma, Neuroendocrine A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round blue cells, granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small (oat) cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)	0	2.13	1	0
Disease Exacerbation [description not available]	0	2.13	1	0
Adenocarcinoma, Basal Cell [description not available]	0	2.13	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	0	2.13	1	0
Androgen-Independent Prostatic Cancer [description not available]	0	2.13	1	0
Prostatic Neoplasms, Castration-Resistant Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.	0	2.13	1	0
Blood Clot [description not available]	0	2.05	1	0
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	0	7.05	1	0
Cirrhoses, Experimental Liver [description not available]	0	2.06	1	0
Granulocytic Leukemia, Chronic [description not available]	0	2.06	1	0
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	0	2.06	1	0
Femoral Fractures Fractures of the femur.	0	2.08	1	0
Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.	0	2.03	1	0

icaritin

Description

Cross-References

Synonyms (42)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Protein Targets (3)

Potency Measurements

Inhibition Measurements

Biological Processes (42)

Molecular Functions (27)

Ceullar Components (9)

Bioassays (78)

Research

Studies (201)

Market Indicators

Research Demand Index: 33.87

Study Types

icaritin

Description

Cross-References

Synonyms (42)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Protein Targets (3)

Potency Measurements

Inhibition Measurements

Biological Processes (42)

Molecular Functions (27)

Ceullar Components (9)

Bioassays (78)

Research

Studies (201)

Market Indicators

Research Demand Index: 33.87

Study Types

Related Drugs (128)

Related Conditions (158)